<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433081</url>
  </required_header>
  <id_info>
    <org_study_id>STU00032878</org_study_id>
    <nct_id>NCT01433081</nct_id>
  </id_info>
  <brief_title>The Effect of Magnesium Sulfate Infusion on the Quality of Recovery of Ambulatory Patients</brief_title>
  <official_title>The Effect of Magnesium Sulfate Infusion on the Quality of Recovery of Ambulatory Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A national survey has revealed that 80% of patients experienced pain after surgery and 86% of
      these patients had moderate, severe or extreme pain (1).Postoperative pain can extend
      recovery room stay after surgery and it is also a common cause of unanticipated admissions
      which have important economic implications(2).More importantly, postoperative pain can lead
      to a poor quality of recovery in ambulatory patients. The Intraoperative use of medications
      that might decrease postoperative pain is therefore highly desirable.

      Some medications such as lidocaine and ketamine have been proved to decrease postoperative
      pain when given during the Intraoperative period in ambulatory patients(3,4) but it is still
      unknown if those medications can in fact lead to a better quality of recovery .

      Magnesium sulfate is a non-competitive calcium antagonist at the N-methyl-D- aspartate (NMDA)
      receptor(5). NMDA receptors have an important role on pain modulation (6). The use of
      Intraoperative magnesium in order to decrease postoperative pain had contradictory results in
      different studies. Some studies have shown a potential benefit of magnesium in decreasing
      postoperative pain (7,8) while others have not demonstrated any benefit (9,10).

      In the ambulatory setting, specifically, Tramer et al. did not find any improvement on
      postoperative pain after an Intraoperative dose of magnesium for patients undergoing
      ilioinguinal hernia repair(11). Koinig et al., however, demonstrated a significant reduction
      in the postoperative analgesic requirements in patients undergoing arthroscopic knee surgery
      (12).

      Even though, the reduction of postoperative opioid requirement has been used in many studies
      in the ambulatory literature, it has been recently questioned by some investigators
      (13).Patients might take more opioid medications but they may not necessarily develop opioid
      related side effects such as nausea and vomiting. A more global evaluation of the patient
      involving several aspects of recovery would be more significant.

      The modified quality of recovery 40(MQOR40) is a validated 40 item instrument to assess the
      quality of postoperative recovery (14). Myles et al. concluded that the MQOR40 would be a
      useful outcome measure to assess the impact on changes in health care delivery (15), but
      anesthesia studies underutilize this instrument.

      As more complex and painful procedures are being done in the ambulatory setting , the use of
      non-opioid strategies to control postoperative pain and to enhance quality of recovery will
      have even a greater role in the anesthetic management of patients. Magnesium has not been
      established as a potential adjuvant in ambulatory patients with conflicting results of
      previous investigators. The main objective of this study is to evaluate if the Intraoperative
      use of magnesium have the ability to improve postoperative quality of recovery in ambulatory
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Recovery Scores Post Operative</measure>
    <time_frame>24 hours post operative</time_frame>
    <description>Quality of recovery scores post operative. Scored on a scale of 40 (poor recovery) to 200 (good recovery).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Opioid consumption after discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pain</condition>
  <condition>Opioid Use, Unspecified, Uncomplicated</condition>
  <arm_group>
    <arm_group_label>Magnesium sulfate infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of magnesium suflate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>.9 normal saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo infusion of .9 normal saline</intervention_name>
    <description>administration of .9 normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>administration of magnesium sulfate</intervention_name>
    <description>administration of magnesium sulfate</description>
    <arm_group_label>Magnesium sulfate infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  undergoing lumpectomy

          -  ASA I and II

          -  Age between 18-64

        Exclusion Criteria:

          -  pregnancy

          -  breastfeeding -history of EKG abnormalities-

          -  kidney disease including: End Stage Renal Disease and polycystic kidney disease

          -  unable to understand the informed consent

          -  use of opioid in the last week

          -  use of calcium channel blockers

          -  Drop-out: surgeon or patient request
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gildasio De Oliveira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prentice Womens Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003 Aug;97(2):534-40, table of contents.</citation>
    <PMID>12873949</PMID>
  </reference>
  <reference>
    <citation>White PF. Multimodal analgesia: its role in preventing postoperative pain. Curr Opin Investig Drugs. 2008 Jan;9(1):76-82. Review.</citation>
    <PMID>18183534</PMID>
  </reference>
  <reference>
    <citation>McKay A, Gottschalk A, Ploppa A, Durieux ME, Groves DS. Systemic lidocaine decreased the perioperative opioid analgesic requirements but failed to reduce discharge time after ambulatory surgery. Anesth Analg. 2009 Dec;109(6):1805-8. doi: 10.1213/ANE.0b013e3181be371b.</citation>
    <PMID>19923506</PMID>
  </reference>
  <reference>
    <citation>Berti M, Baciarello M, Troglio R, Fanelli G. Clinical uses of low-dose ketamine in patients undergoing surgery. Curr Drug Targets. 2009 Aug;10(8):707-15. Review.</citation>
    <PMID>19702519</PMID>
  </reference>
  <reference>
    <citation>Mayer ML, Westbrook GL, Guthrie PB. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature. 1984 May 17-23;309(5965):261-3.</citation>
    <PMID>6325946</PMID>
  </reference>
  <reference>
    <citation>Begon S, Pickering G, Eschalier A, Mazur A, Rayssiguier Y, Dubray C. Role of spinal NMDA receptors, protein kinase C and nitric oxide synthase in the hyperalgesia induced by magnesium deficiency in rats. Br J Pharmacol. 2001 Nov;134(6):1227-36.</citation>
    <PMID>11704642</PMID>
  </reference>
  <reference>
    <citation>Ryu JH, Kang MH, Park KS, Do SH. Effects of magnesium sulphate on intraoperative anaesthetic requirements and postoperative analgesia in gynaecology patients receiving total intravenous anaesthesia. Br J Anaesth. 2008 Mar;100(3):397-403. doi: 10.1093/bja/aem407.</citation>
    <PMID>18276652</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2011</study_first_posted>
  <results_first_submitted>November 13, 2013</results_first_submitted>
  <results_first_submitted_qc>February 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 2, 2014</results_first_posted>
  <last_update_submitted>February 19, 2014</last_update_submitted>
  <last_update_submitted_qc>February 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Gildasio De Oliveira</investigator_full_name>
    <investigator_title>Gildasio De Oliveira, M.D. Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled consecutively from 2/2011 through 4/2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Magnesium Sulfate Infusion</title>
          <description>Administration of magnesium suflate</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Normal saline infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Magnesium Sulfate Infusion</title>
          <description>Administration of magnesium suflate</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>.9 normal saline infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="6.15"/>
                    <measurement group_id="B2" value="52" spread="7.7"/>
                    <measurement group_id="B3" value="52" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality of Recovery Scores Post Operative</title>
        <description>Quality of recovery scores post operative. Scored on a scale of 40 (poor recovery) to 200 (good recovery).</description>
        <time_frame>24 hours post operative</time_frame>
        <population>Two drop outs for either arm were removed from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnesium Sulfate Infusion</title>
            <description>Administration of magnesium suflate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Recovery Scores Post Operative</title>
          <description>Quality of recovery scores post operative. Scored on a scale of 40 (poor recovery) to 200 (good recovery).</description>
          <population>Two drop outs for either arm were removed from analysis.</population>
          <units>units on scale 40 (low) - 200 (high)</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183" lower_limit="173" upper_limit="188"/>
                    <measurement group_id="O2" value="159" lower_limit="153" upper_limit="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption</title>
        <description>Opioid consumption after discharge</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Magnesium Sulfate Infusion</title>
            <description>Administration of magnesium suflate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>.9 normal saline infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption</title>
          <description>Opioid consumption after discharge</description>
          <units>miligram morphine equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="0" upper_limit="20"/>
                    <measurement group_id="O2" value="30" lower_limit="20" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <desc>Nausea in the post operative period</desc>
      <group_list>
        <group group_id="E1">
          <title>Magnesium Sulfate Infusion</title>
          <description>Administration of magnesium suflate</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>.9 normal saline infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.o</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea in 24 hour post operative period.</description>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Vomiting in 24 hour period post operative.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We only examined subjects with normal kidney function that were at low risk for magnesium toxicity. It is possible that the current intervention regimen could have led to toxic levels in higher risk patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gildasio De Oliveira MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-472-3573</phone>
      <email>g-jr@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

